$10,685.66 speaking Payment -- AbbVie Inc to Dr. Timothy Rogers

AbbVie compensates Gastroenterologist Timothy Rogers over $10,000 for speaking services

This page provides a detailed analysis of a $10,685.66 speaking payment from AbbVie Inc to Dr. Timothy Rogers. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$10,685.66
Payment Typespeaking
Payment NatureCompensation for serving as faculty or as a speaker
Pharmaceutical CompanyAbbVie Inc
PhysicianDr. Timothy Rogers
NPI Number1282836498
Physician SpecialtyGastroenterology
LocationDallas, TX
Date of Payment2024-08-20
Related Drug/DeviceTagrisso
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

AbbVie Inc made a $10.7K speaking payment to Timothy Rogers, a Gastroenterology specialist in Dallas, TX. The payment was associated with Tagrisso. AbbVie Inc. paid Timothy Rogers $10,685.66 on August 20, 2024, for speaking engagements related to Tagrisso. The payment was for serving as faculty or a speaker, indicating an educational or promotional role. This payment falls under the 'speaking' category, which is a common form of compensation in the pharmaceutical industry.

Patient Guidance: What This Payment Means for You

This payment was for a doctor's educational services to a pharmaceutical company, not for your personal medical care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements are common in the pharmaceutical industry, particularly for specialists like gastroenterologists who may educate peers on new treatments or drugs.

Regulatory Context: Sunshine Act Requirements

This payment is reportable under the Sunshine Act, requiring disclosure of transfers of value from drug and device manufacturers to physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $10.7K payment for?

This was a speaking payment of $10.7K from AbbVie Inc to Timothy Rogers, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Tagrisso. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Timothy Rogers accept pharmaceutical money?

Yes, Timothy Rogers received this $10.7K payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Timothy Rogers's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $10.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Gastroenterology?

To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Timothy Rogers's relationship with AbbVie Inc?

The payment amount is substantial, suggesting a significant speaking engagement. This $10.7K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Gastroenterology?

The specific drug mentioned, Tagrisso, indicates the focus of the speaking engagement.

What should patients do after learning about this payment?

This payment was for a doctor's educational services to a pharmaceutical company, not for your personal medical care.

What else should I know about this speaking payment?

The payment date is recent, falling within the current reporting period.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.